Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Muscle Invasive Bladder Cancer

Interventions

BIOLOGICAL: CG0070
BIOLOGICAL: Pembrolizumab Injection
OTHER: n-dodecyl-B-D-maltoside

Sponsor

CG Oncology, Inc.

Collaborators

[object Object]